Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...

AnaptysBio plans to advance rosnilimab for RA, with a program update expected in the first half of 2026. Read why ANAB stock ...

One way we can prevent that is by eating certain foods. She recommends following the MIND diet since it has been found to be the most beneficial for brain health and Alzheimer’s prevention. It ...

Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected ...

No drugs are specifically indicated for MASLD, but the FDA has granted accelerated approval to two drugs for non-cirrhotic ...

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic ...

Net Loss -- Net loss for Q3 2025 was $2.3 million compared to a $6.9 million loss in Q3 2024, driven by higher gross profit, reduced operating expenses, and partially offset by higher interest expense ...

Discover 50 practical tips to save money eating out without missing the fun—smart ways to enjoy dining out on any budget.

Study conducted in collaboration with the Alzheimer’s Clinical Trials ConsortiumPURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX ...

Dr. Phillip Connor, Research Fellow at Princeton University, and long-time Arlington resident has published a new book, “MAKE ...

CARDIAMP CMI Cohort Results -- In the open-label rolling cohort (n=5), patients saw an average 80-second increase in exercise ...

Q3 2025 Earnings Call November 13, 2025 9:00 AM ESTCompany ParticipantsMeghan MacEachern - Vice President of Investor Relations ...